Dipeptidyl Peptidase-4 Inhibitors and Cancer Risk in Patients with Type 2 Diabetes: a Meta-analysis of Randomized Clinical Trials

Overview

Journal Sci Rep

Specialty Science

Date 2017 Aug 17

PMID 28811622

Citations 28

Authors

Ming Zhao

Jiayi Chen

Yanyan Yuan

Zuquan Zou

Xiaolong Lai

Daud M Rahmani

Fuyan Wang

Yang Xi

Qin Huang

Shizhong Bu

Affiliations

Soon will be listed here.

Abstract

Some recent studies have suggested that the use of dipeptidyl peptidase-4 inhibitors (DPP4i) is associated with cancer development. However, some other studies suggest no such association. The aim of the present study was to evaluate the effect of DPP4i on the risk of developing cancers. The electronic databases PubMed, Medline, EMBASE, Web of Science and Cochrane Library and the clinical trial registry were searched for published and unpublished randomized clinical trials on humans. Eligible studies were RCTs conducted in patients with type 2 diabetes mellitus, comparing DPP4i with a placebo or other active drugs. A total of 72 trials with 35,768 and 33,319 patients enrolled for DPP4i and the comparison drugs, respectively. Overall, no significant associations were detected between the use of DPP4i and cancer development, in comparison with the use of other active drugs or placebo. The results were consistent across pre-defined subgroups stratified by type of DPP4i, type of cancer, drug for comparison, trial duration, or baseline characteristics. The results of this meta-analysis suggest that patients with type 2 diabetes treated with DPP4i do not have a higher risk of developing cancers than patients treated with a placebo or other drugs.

Citing Articles

Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study.

Krishnan A, Schneider C, Arkenau H, Mauro E, Forner A, Butsch W J Clin Transl Endocrinol. 2024; 38:100370.

PMID: 39386155 PMC: 11460491. DOI: 10.1016/j.jcte.2024.100370.

PPAR-γ agonist pioglitazone and the risks of malignancy among type2 diabetes mellitus patients.

See L, Wu C, Tsai C, Lee C, Chen J, Jenq C Acta Diabetol. 2024; .

PMID: 39347851 DOI: 10.1007/s00592-024-02378-y.

Repurposing metabolic regulators: antidiabetic drugs as anticancer agents.

Dhas Y, Biswas N, M R D, Jones L, Ashili S Mol Biomed. 2024; 5(1):40.

PMID: 39333445 PMC: 11436690. DOI: 10.1186/s43556-024-00204-z.

Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort study.

Chou O, Chauhan V, Chung C, Lu L, Lee T, Ng Z Gastric Cancer. 2024; 27(5):947-970.

PMID: 38856768 PMC: 11335951. DOI: 10.1007/s10120-024-01512-7.

Role of SGLT2 Inhibitors, DPP-4 Inhibitors, and Metformin in Pancreatic Cancer Prevention.

Laeeq T, Ahmed M, Sattar H, Zeeshan M, Ali M Cancers (Basel). 2024; 16(7).

PMID: 38611003 PMC: 11011099. DOI: 10.3390/cancers16071325.

References

Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M . 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012; 380(9840):475-83. DOI: 10.1016/S0140-6736(12)60691-6. View

Scirica B, Bhatt D, Braunwald E, Steg P, Davidson J, Hirshberg B . Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369(14):1317-26. DOI: 10.1056/NEJMoa1307684. View

Bruno G, Runzo C, Cavallo-Perin P, Merletti F, Rivetti M, Pinach S . Incidence of type 1 and type 2 diabetes in adults aged 30-49 years: the population-based registry in the province of Turin, Italy. Diabetes Care. 2005; 28(11):2613-9. DOI: 10.2337/diacare.28.11.2613. View

Tseng C . Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes. Oncotarget. 2016; 8(12):19057-19064. PMC: 5386669. DOI: 10.18632/oncotarget.12137. View

Monami M, Dicembrini I, Mannucci E . Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013; 16(1):48-56. DOI: 10.1111/dom.12176. View

Boyle J, Engelgau M, Thompson T, Goldschmid M, Beckles G, Timberlake D . Estimating prevalence of type 1 and type 2 diabetes in a population of African Americans with diabetes mellitus. Am J Epidemiol. 1999; 149(1):55-63. DOI: 10.1093/oxfordjournals.aje.a009728. View

Gokhale M, Buse J, Gray C, Pate V, Marquis M, Sturmer T . Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study. Diabetes Obes Metab. 2014; 16(12):1247-56. PMC: 4227935. DOI: 10.1111/dom.12379. View

Meier J, Nauck M . Risk of pancreatitis in patients treated with incretin-based therapies. Diabetologia. 2014; 57(7):1320-4. DOI: 10.1007/s00125-014-3231-y. View

Pratley R, Nauck M, Bailey T, Montanya E, Filetti S, Garber A . Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care. 2012; 35(10):1986-93. PMC: 3447855. DOI: 10.2337/dc11-2113. View

10.

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

11.

Gale E . Collateral damage: the conundrum of drug safety. Diabetologia. 2009; 52(10):1975-82. DOI: 10.1007/s00125-009-1491-8. View

12.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010; 8(5):336-41. DOI: 10.1016/j.ijsu.2010.02.007. View

13.

Tarapues M, Cereza G, Figueras A . Association of musculoskeletal complaints and gliptin use: review of spontaneous reports. Pharmacoepidemiol Drug Saf. 2013; 22(10):1115-8. DOI: 10.1002/pds.3503. View

14.

Yoon K, Lee J, Kim J, Cho J, Choi Y, Ko S . Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006; 368(9548):1681-8. DOI: 10.1016/S0140-6736(06)69703-1. View

15.

Ahren B, Johnson S, Stewart M, Cirkel D, Yang F, Perry C . HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014; 37(8):2141-8. DOI: 10.2337/dc14-0024. View

16.

Monami M, Dicembrini I, Martelli D, Mannucci E . Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011; 27 Suppl 3:57-64. DOI: 10.1185/03007995.2011.602964. View

17.

Nathan D . Finding new treatments for diabetes--how many, how fast... how good?. N Engl J Med. 2007; 356(5):437-40. DOI: 10.1056/NEJMp068294. View

18.

Choi H, Kim J, Lim S, Kim G, Yun H, Choi H . Dipeptidyl peptidase 4 promotes epithelial cell transformation and breast tumourigenesis via induction of PIN1 gene expression. Br J Pharmacol. 2015; 172(21):5096-109. PMC: 4687806. DOI: 10.1111/bph.13274. View

19.

Duval S, Tweedie R . Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; 56(2):455-63. DOI: 10.1111/j.0006-341x.2000.00455.x. View

20.

Tseng C . Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes. Oncotarget. 2016; 7(17):24871-9. PMC: 5029749. DOI: 10.18632/oncotarget.8399. View